Restoring Synaptic Architecture

The Future of
Neurological Therapeutics
Starts with Connection.

WYYS is developing a new class of antibody therapeutics designed to restore synaptic architecture and support functional recovery in neurological diseases.

Reconnect.Connection
Restore.Architecture
Recover.Function
Discover Our Approach
01

Synaptic Dysfunction

Different disorders.
A shared vulnerability.

Many neurological disorders converge on synaptic dysfunction.

Alzheimer's disease
Parkinson's disease
ALS
Frontotemporal dementia
Schizophrenia
Autism spectrum disorder
Synaptic
Dysfunction
02

Our Approach

Treating the connection,
not only the pathology.

Current disease-modifying strategies often focus on pathological proteins. WYYS is developing a complementary therapeutic approach that directly addresses synaptic dysfunction by restoring synaptic architecture and supporting functional recovery.

Current Therapeutic Strategy Pathological protein Clearance Disease modification
WYYS Strategy Synaptic dysfunction Restore architecture Support function
03

The 3R Philosophy

Reconnect. Restore. Recover.

Three principles. One therapeutic direction.

01

Reconnect.

Re-establish the structural relationships required for effective neuronal communication.

02

Restore.

Support the organization and stability of synaptic architecture.

03

Recover.

Enable the conditions required to support meaningful neurological function.

04

Our Platform

Engineering Antibody Therapeutics
for Synaptic Connectivity.

A synapse-focused antibody platform designed to restore synaptic architecture and support functional connectivity.

ArchitectureRestore synaptic structure
AntibodyEngineer precision therapeutics
ConnectionSupport functional connectivity
05

Development

Advancing from hypothesis
toward experimental validation.

Our platform combines scientific rationale, structural biology, computational protein design and molecular simulation to move therapeutic concepts toward recombinant development and biological validation.

Scientific hypothesisEstablished
Computational design frameworkEstablished
Recombinant antibody developmentCurrent stage
In vitro validationUpcoming
In vivo validationUpcoming
06

About WYYS

From Neural Plasticity
to Synaptic Therapeutics.

Hajun Yoon, MD Founder

WYYS was founded by Hajun Yoon, MD, a physician whose work has spanned neuroscience research, clinical practice, structural biology, antibody engineering, computational protein design and molecular simulation.

WYYS was created to pursue a simple scientific question: could restoring synaptic architecture become a new therapeutic strategy for neurological disease?

Connect With WYYS

Building the next generation
of neurological therapeutics.

contact@wyys.bio